Dr. William Williams reports

BRIACELL ARRANGES SCALABLE MANUFACTURING WITH FUJIFILM BIOTECHNOLOGIES FOR BRIA-IMT

Briacell Therapeutics Corp. has signed a manufacturing arrangement with Fujifilm Biotechnologies California, a leading contract development and manufacturing organization specializing in cell therapies, to support the continuing pivotal phase 3 clinical development and potential future commercial supply of Briacell's lead clinical candidate, Bria-IMT, an off-the-shelf allogenic cell therapy.

Bria-IMT is currently being evaluated in Briacell's pivotal phase 3 study of Bria-IMT in combination with an immune checkpoint inhibitor in advanced metastatic breast cancer.

"Securing manufacturing capacity with Fujifilm, a global leader in cell therapy manufacturing, represents a key milestone in our Bria-IMT development and potential commercialization strategy as we work toward our goal of bringing this novel immunotherapy candidate to patients with metastatic breast cancer," said Dr. William V. Williams, MD, president and chief executive officer of Briacell.

About Briacell Therapeutics Corp.

Briacell is a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care.

We seek Safe Harbor.